Aura Biosciences: A Pivotal Trial Engineered With Room To Spare
Aura Biosciences expects pivotal Phase 3 bel-sar data in early choroidal melanoma in 2027, funded by $323.8 million of cash into the first…
Equity Eagle NASDAQ
Aura Biosciences, Inc.
AURA
1 story
$628M Market cap · 2026-10-30
Equity Eagle 